Welcome!

News Feed Item

Treatment for Facial Redness Associated With Rosacea Now Available in the UK

LONDON, April 17, 2014 /PRNewswire/ --

Mirvaso® (brimonidine) 3 mg/g gel an alpha-2 adrenergic agonist indicated for the symptomatic treatment of the redness (facial erythema) associated with rosacea in adult patients, is now available in the UK.

     (Photo: http://photos.prnewswire.com/prnh/20140416/680993-INFO )

The active ingredient, brimonidine, restricts excessive blood flow to the upper layers of the skin. The topical gel is applied to the forehead, chin, nose and cheeks, and can reduce facial redness for up to 12 hours[1]. Mirvaso offers a new and effective management option for a commonly misunderstood inflammatory skin condition.

Dr Anton Alexandroff, Consultant Dermatologist at University Hospitals Leicester, said: "Rosacea is often misunderstood and until now we have been extremely limited in the options we can offer people suffering from facial redness. Typically the symptoms associated with rosacea get worse if left untreated so it's key that we recognise and treat this condition."

Rosacea is a progressive, long-term condition that affects over 10% of adults in the UK[2]. It is characterised by facial redness and flushing called erythema[3], caused by abnormal blood flow to the skin's top layers. It can lead to bumps and pimples (papules and pustules)[3] and, in severe cases, facial disfiguration, if left unmanaged.

Dr Ellie Cannon, General Practitioner, added: "Many people underestimate the impact of the flushing and redness associated with rosacea: if it is not appropriately managed it can severely impact a person's life, causing anxiety, embarrassment, low self-esteem and isolation. It is often discounted simply as blushing but the sad truth is that people are judged negatively as a result of this very visible condition."

Rosacea's exact cause is unknown but chronic inflammation is believed to play a key role. Certain triggers: heat, cold, intense physical exercise, alcohol and caffeine[4], can intensify it. Until now, rosacea management was limited to dietary and lifestyle adjustments like avoiding key triggers. Some patients are prescribed anti-inflammatory antibiotics - which treat the pimples and pustules associated with rosacea but fail to combat facial redness and flushing[4].

To access the SPC, please visit: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002642/WC500163121.pdf

For further information about the disease, please visit: http://www.myrosacea.co.uk

For further information about the company, please visit: http://www.galderma.co.uk

Galderma - a global company exclusively dedicated to dermatology

Galderma is a global company founded in 1981 committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world.  The company has 33 wholly-owned affiliates with a worldwide network of distributors and more than 5,000 employees. Galderma's extensive product portfolio is available in 80 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.

With approximately 19% of revenues invested each year to discover and develop new products and access innovative technologies, the company is one of the world's leading investors in dermatology R&D. Five state-of-the-art R&D centers and five manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.

Strategic brands include Epiduo, Efracea, Etrivex, Differin, Mirvaso®, Rozex/MetroGel, Silkis, Loceryl/Curanail, Cetaphil, Metvix, Azzalure, Restylane and Emervel.

References  

1. J Fowler, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, vehicle- controlled pivotal studies. J Drugs Dermatol 2013;12(6): 650-656.

2. NHS Choices. Rosacea Introduction. http://www.nhs.uk/conditions/Rosacea/Pages/Introduction.aspx  Last accessed March 2014.

3. Powell FC. Rosacea. N Engl J Med. 2005;352:793-80.

4. NICE guidelines. Rosacea.  http://cks.nice.org.uk/rosacea#!topicsummary Last accessed March 2014.

MRV/059/0414
Date of Preparation: April 2014

Contacts: 

Galderma (UK) Ltd
Ruth Baxter
Group Product Manager
Tel: +44(0)1923-208950
E-mail: [email protected]

Ruder Finn
Donna Wright
Account Director
Tel: +44(0)20-7438-3085
E-mail: [email protected]


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...
Enterprise architects are increasingly adopting multi-cloud strategies as they seek to utilize existing data center assets, leverage the advantages of cloud computing and avoid cloud vendor lock-in. This requires a globally aware traffic management strategy that can monitor infrastructure health across data centers and end-user experience globally, while responding to control changes and system specification at the speed of today’s DevOps teams. In his session at 20th Cloud Expo, Josh Gray, Chie...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. Jack Norris reviews best practices to show how companies develop, deploy, and dynamically update these applications and how this data-first...
Intelligent Automation is now one of the key business imperatives for CIOs and CISOs impacting all areas of business today. In his session at 21st Cloud Expo, Brian Boeggeman, VP Alliances & Partnerships at Ayehu, will talk about how business value is created and delivered through intelligent automation to today’s enterprises. The open ecosystem platform approach toward Intelligent Automation that Ayehu delivers to the market is core to enabling the creation of the self-driving enterprise.
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Consumers increasingly expect their electronic "things" to be connected to smart phones, tablets and the Internet. When that thing happens to be a medical device, the risks and benefits of connectivity must be carefully weighed. Once the decision is made that connecting the device is beneficial, medical device manufacturers must design their products to maintain patient safety and prevent compromised personal health information in the face of cybersecurity threats. In his session at @ThingsExpo...
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution and join Akvelon expert and IoT industry leader, Sergey Grebnov, in his session at @ThingsExpo, for an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
Because IoT devices are deployed in mission-critical environments more than ever before, it’s increasingly imperative they be truly smart. IoT sensors simply stockpiling data isn’t useful. IoT must be artificially and naturally intelligent in order to provide more value In his session at @ThingsExpo, John Crupi, Vice President and Engineering System Architect at Greenwave Systems, will discuss how IoT artificial intelligence (AI) can be carried out via edge analytics and machine learning techn...